Detailed Narrative
International Markets Drive Outperformance
Alembic's international business was the primary growth engine this quarter, with US revenue growing 21% and ROW markets surging 31%. The US growth was underpinned by the successful launch of Entresto and three other products, despite ongoing pricing erosion. In ROW, 85% of the business now comes from regulated markets like Europe, Canada, and Australia, where the company maintains a 20% CAGR over the long term⏳.
Strategic Pivot to US Branded Specialty
The acquisition of Utility Therapeutics marks Alembic's entry into the US branded market with Pivya, a product for urinary tract infections. The deal involves a $4 million upfront payment and $12 million in total milestones. While the launch in late Q4 FY26 will require a dedicated field force and cause a near-term profitability hit, management views this as a critical de-risking strategy from the volatile generic business.
R&D Focus on Complex Generics and Peptides
R&D spend reached 10% of revenue this quarter, driven by development in complex injectables and peptides. Management confirmed they are working on Tirzepatide (Mounjaro) and have already produced batches, contributing to the cost spike. Despite the quarterly increase, the company maintained its full-year R&D guidance of ₹600-650 crores, expecting the ratio to normalize to 8% by year-end.
Margin Expansion Path to 20%
Management has set a clear target to reach 20% EBITDA margins within the next two years. This expansion is expected to come from operating leverage as utilization increases at the new injectable and oncology facilities, which are currently running at lower-than-anticipated levels. Improved productivity in the India field force and a shift toward higher-value complex products are also cited as key margin drivers.
India Business Navigates GST Transition
The India Branded Business grew a modest 5% YoY to ₹639 crores, impacted by a temporary billing pause during the migration to GST 2.0. While segments like Gynecology and Animal Health outperformed, the core acute business faced a high base effect from the previous year. Management expects growth to catch up📎 with the Indian Pharmaceutical Market (IPM) as productivity improvements in the field force take hold in FY27.